Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) Operating Expenses (2020 - 2025)

Tango Therapeutics has reported Operating Expenses over the past 6 years, most recently at $41.9 million for Q4 2025.

  • Quarterly results put Operating Expenses at $41.9 million for Q4 2025, down 7.02% from a year ago — trailing twelve months through Dec 2025 was $173.7 million (up 15.25% YoY), and the annual figure for FY2025 was $173.7 million, down 7.46%.
  • Operating Expenses for Q4 2025 was $41.9 million at Tango Therapeutics, up from $39.7 million in the prior quarter.
  • Over the last five years, Operating Expenses for TNGX hit a ceiling of $49.4 million in Q2 2024 and a floor of $7.5 million in Q3 2024.
  • Median Operating Expenses over the past 5 years was $36.9 million (2022), compared with a mean of $35.3 million.
  • Biggest five-year swings in Operating Expenses: skyrocketed 4811128.81% in 2021 and later plummeted 79.34% in 2024.
  • Tango Therapeutics' Operating Expenses stood at $27.7 million in 2021, then soared by 33.49% to $37.0 million in 2022, then grew by 9.37% to $40.4 million in 2023, then rose by 11.33% to $45.0 million in 2024, then dropped by 7.02% to $41.9 million in 2025.
  • The last three reported values for Operating Expenses were $41.9 million (Q4 2025), $39.7 million (Q3 2025), and $44.1 million (Q2 2025) per Business Quant data.